Name | Value |
---|---|
Revenues | 3,432.0K |
Cost of Revenue | 2,512.0K |
Gross Profit | 920.0K |
Operating Expense | 2,994.0K |
Operating I/L | -2,074.0K |
Other Income/Expense | -5.0K |
Interest Income | 0.0K |
Pretax | -2,079.0K |
Income Tax Expense | -0.0K |
Net Income/Loss | -2,079.0K |
Precipio, Inc. is a healthcare solutions company in the United States, specializing in diagnostic blood cancer testing services. The company offers a range of products and services including IV-Cell, HemeScreen genetic diagnostic panels, ICE-COLD PCR technology, and COVID-19 antibody tests. It generates revenue through the sale of its proprietary cell culture media, genetic diagnostic panels, ICE-COLD-PCR technology kits, and COVID-19 antibody tests. Additionally, Precipio, Inc. collaborates with academic institutions focused on cancer research, diagnostics, and treatment, further enhancing its product offerings and market presence.